CELGENE
LIVE

Serial Number

76515116

Owner

Celgene Corporation

Attorney

Marilyn F. Kelly

First Use Date

Dec 31, 1986

Filing Date

May 19, 2003

Add to watchlist:

No watchlists yet
View on USPTO

CELGENE Trademark

Serial Number: 76515116 • Registration: 2888517

CELGENE is a trademark filed by Celgene Corporation on May 19, 2003. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Celgene Corporation (868 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

May 19, 2003

Registration Date

September 28, 2004

First Use Anywhere

December 31, 1986

First Use in Commerce

December 31, 1986

Published for Opposition

July 6, 2004

Goods & Services

[ educational classes and programs in the field of thalidomide and safety issues pertaining to thalidomide, and distribution of written materials therewith ]

[ manufacturing pharmaceutical products for others; custom synthesis of DNA to the order and specification of others; custom manufacturing services, namely, manufacturing agrochemicals to the specification of others ]

[ biological preparations for medical purposes, namely for use in the treatment of immunological, inflammatory and neurological disorders; pharmaceuticals, genomic and biological agents for use in the fields of immunological, inflammatory and neurological disorders for the identification, analysis, prevention, detection, diagnosis, prognosis and treatment; biological preparations for use in medicinal tests, inoculations, and treatment of diseases, namely, immunological, inflammatory and neurological disorders and cancer; culture media, namely, tissue culture media and bacteriogical culture media for medical use; medicinal and biological preparations for pharmaceutical and clinical use, namely, preparations for the inhibition of gene expression working at DNA, transcription, RNA or translation processes, and modulation of immune system ]

[ biochemical catalysts for use in medical research; biological preparations for medical purposes, namely, for use in the research of immunological, inflammatory and neurological disorders; catalysts for use in the manufacture of pharmaceuticals; chemical preparations, namely, chemical reagents for scientific purposes; [ enzyme preparations for industrial purposes; enzymes for industrial purposes; ] proteins for [ industrial and ] human consumption, namely, animal proteins, genetic testing reagents for scientific laboratory use, namely, DNA probes; [ chemical preparations used to protect crops in the agricultural and horticultural field; ] medicinal and biological preparations for medical laboratory use, namely, preparations for the inhibition of gene expression working at DNA, transcription, RNA or translation processes, and modulation of immune system ]

research in the fields of chemicals and pharmaceuticals; product safety testing in the fields of chemicals and pharmaceuticals; research and development of new products for others in the fields of chemicals and pharmaceuticals; providing clinical laboratory testing services, namely, pharmacogenetic tests, predictive medical tests, personalized medical tests, gene sequencing-based tests and genotyping base on the assessment, development and application of genomic discoveries in the pharmaceutical, informatics and clinical diagnostic industries; providing medical and pharmaceutical research information; scientific research services; design for others in the field of DNA-based assays, DNA sequencing protocols, immunoassay and methods for drug discovery; scientific research, namely, development of pharmaceuticals or diagnostic methods for others [ ; agrochemical product development for others ]

Filing History

NOTICE OF ACCEPTANCE OF PARTIAL SEC. 8 & 9 EMAILED
Dec 20, 2024 NP89
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
Dec 20, 2024 RNL2
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
Dec 20, 2024 9G8P
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
Dec 20, 2024 8PRT
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 20, 2024 APRE
TEAS SECTION 8 & 9 RECEIVED
Sep 11, 2024 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Sep 28, 2023 REM2
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 9, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 9, 2022 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Dec 9, 2022 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 9, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 9, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 9, 2022 COAR
NOTICE OF SUIT
Sep 10, 2020 NOSU
NOTICE OF SUIT
Apr 20, 2020 NOSU
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 28, 2015 TCCA
NOTICE OF ACCEPTANCE OF SEC. 8 - MAILED
Oct 3, 2013 NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Oct 2, 2013 NAS8
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Oct 2, 2013 RNL1
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
Oct 2, 2013 9G8P
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
Oct 2, 2013 8PRT
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 2, 2013 APRE
REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED
Sep 30, 2013 89AF
TEAS SECTION 8 & 9 RECEIVED
Sep 30, 2013 E89R
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Oct 20, 2009 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 20, 2009 APRE
TEAS SECTION 8 & 15 RECEIVED
Oct 2, 2009 E815
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 16, 2005 COAR
REGISTERED-PRINCIPAL REGISTER
Sep 28, 2004 R.PR
PUBLISHED FOR OPPOSITION
Jul 6, 2004 PUBO
NOTICE OF PUBLICATION
Jun 16, 2004 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 30, 2004 CNSA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 19, 2004 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 15, 2004 CNSA
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 19, 2003 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 19, 2003 TROA
NON-FINAL ACTION MAILED
Dec 12, 2003 CNRT
ASSIGNED TO EXAMINER
Nov 29, 2003 DOCK